Yokogawa Announces Synaptic Business Automation(TM) Concept for Industrial Automation and Control Business
Yokogawa Electric Corporation (TOKYO:6841) announces Synaptic Business Automation(TM), a new industrial automation and control business concept that expresses the company’s commitment to working with its customers to sustain their creation of corporate value. Based on the ideals expressed in the Synaptic Business Automation concept, Yokogawa will help companies achieve a transformation in how they conduct their business.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171105005001/en/
Creation of value through Synaptic Business Automation for profitable and sustainable growth (Graphic: Yokogawa Electric Corporation)
A Closer Look at Synaptic Business Automation
Manufacturers face a variety of challenges today, ranging from volatile shifts in the prices of crude oil and other raw materials and stiffening environmental and safety regulations to structural changes in their industries. To remain competitive, they must have the agility to adapt quickly to change.
To guide its efforts to assist companies in meeting such challenges, Yokogawa adheres to a vision statement that reads, “Through ‘Process Co-Innovation,’ Yokogawa creates new value with its clients for a brighter future.” We help companies improve efficiency and profitability by getting their various business units to work together more effectively and by eliminating barriers that impede the flow of information and goods throughout the supply chain and between companies.
As the Internet of Things gains traction, a digitalization of processes is underway whereby the use of big data and artificial intelligence is yielding valuable insights needed to make business decisions. The Synaptic Business Automation concept clearly expresses Yokogawa’s commitment to using the latest information technologies and its decades of experience with plant management and industrial processes, portfolio of automation solutions, and consulting expertise to help its customers transform their businesses.
The Synaptic Business Automation concept takes its name from the synapse, a structure in the nervous system that plays a role in the transfer of signals to other parts of the human body. Synaptic Business Automation expresses an ideal state for a business whereby the synthesizing of data, systems, organizations, knowledge, and supply chains adds value and strengthens competitiveness. The linked data on manufacturing processes, plant operations, human resources, and supply chains can be organized, integrated, controlled, broken down, and analyzed to yield insightful decisions at various levels in the organization, from operations in the field to corporate management.
Ways in which Synaptic Business Automation creates corporate value for our customers:
Adapt more flexibly to changes in such areas as health, safety, security and the environment (HSSE), organizational optimization, and regulatory compliance.
Optimize the total expenditure (TOTEX) components of capital expenditure (CAPEX) and operational expenditure (OPEX) over the entire lifecycle of a plant, and improve reliability. Also, directly create value by solving issues and optimizing operations throughout a supply chain, thereby enhancing productivity and profitability.
Work with specific customers to create new business models that foster manufacturing excellence by such means as supplying cloud-based services that drive collaboration with their customers and suppliers and to introduce environmentally friendly manufacturing practices that are essential for a sustainable society.
Yokogawa has many years of experience in working with operational technology (OT). By combining its in-depth knowledge of plant management, operations, industries, and processes, its portfolio of automation and other information technology solutions, and its consulting expertise, the company is uniquely positioned to create new value. Working together with its customers based on the Co-innovating tomorrow (R) corporate brand slogan, Yokogawa is committed to helping them achieve the ideals expressed in its Synaptic Business Automation concept.
For more information
Yokogawa's global network of 113 companies spans 60 countries. Founded in 1915, the US$3.5 billion company engages in cutting-edge research and innovation. Yokogawa is active in the industrial automation and control (IA), test and measurement, and aviation and other businesses segments. The IA segment plays a vital role in a wide range of industries including oil, chemicals, natural gas, power, iron and steel, pulp and paper, pharmaceuticals, and food. Targeting this segment, Yokogawa helps companies maximize their profits by offering a wide range of highly reliable products and working with the subsidiary KBC Advanced Technologies to provide premium solutions and services. For more information about Yokogawa, please visit www.yokogawa.com
The names of corporations, organizations, and products herein are either trademarks or registered trademarks of their respective holders.
Yokogawa Electric Corporation
Public Relations, Integrated Communications Center
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 05:00 | Pressemelding
BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac
Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 04:05 | Pressemelding
Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations
Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth15.8.2018 23:40 | Pressemelding
Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per
CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 22:37 | Pressemelding
Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He
Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 17:43 | Pressemelding
SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.
Rimini Street Receives Asia-Pacific Stevie Award for Customer Service Innovation15.8.2018 17:05 | Pressemelding
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced it has been honored with a Stevie® Award in the Innovation in Customer Service Management, Planning & Practice category for its ultra-responsive, premium level service in the Asia-Pacific region. This honor marks the Company’s 12th Stevie Award win this year, and the second consecutive year the Company has been recognized by the Asia-Pacific Stevie Awards. Rimini Street recently earned Stevie Awards in several categories, including Company of the Year from the 2018 American Business Awards® and Customer Service Department of the Year from the 2018 Stevie Awards for Sales & Customer Service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005580/en/ Rimini Street Receives Asia-Pacific Stevie Award for Customer Service Innovat